Jeannie T Lee

This inventor holds 28 USPTO granted patents and 24 published patent applications and 6 EPO patents, primarily in Gene Regulation. Top assignees: The General Hospital Corporation, Translate Bio, Inc.. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeannie T Lee. Retrieved from https://idiyas.com/inventor/jeannie-t-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 24)

% Patents Active = 96.4

EPO Patents = 6 (Patent Applications = 23)

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 86(Granted Patents)

Location History:

Weston, MA (US) (2015 - 2016)
Cambridge, MA (US) (2017 - 2021)
Boston, MA (US) (2016 - 2024)

Company Filing History:

27 out of 3,073

The General Hospital Corporation

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

Areas of Expertise:

Gene Modulation

Cellular Stress Response

X Chromosome Reactivation

MECP2 Expression

Polycomb-associated RNAs

CTCF RNA Interactome

ATRX-dependent Repression

Hemoglobin Gene Family

SMN Gene Family

X-inactivation Escapee Genes

Stem Cell Identification

RNA-YY1 Interactions

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12157888 - Modulating the cellular stress response (2024-12-03),

2. 11912994 - Methods for reactivating genes on the inactive X chromosome (2024-02-27),

3. 11788089 - Compositions and methods for modulating MECP2 expression (2023-10-17),

4. 11401518 - Methods of reducing expression of x-inactivation escapee genes and autosomal genes (2022-08-02),

5. 11130951 - Modulating the cellular stress response (2021-09-28),

6. 11066673 - Polycomb-associated non-coding RNAs (2021-07-20),

7. 11001841 - CCCTC-binding factor (CTCF) RNA interactome (2021-05-11),

8. 10961532 - Methods for reactivating genes on the inactive X chromosome (2021-03-30),

9. 10900036 - RNA interactome of polycomb repressive complex 1 (PRC1) (2021-01-26),

10. 10858650 - Methods for modulating ATRX-dependent gene repression (2020-12-08),

11. 10837014 - Compositions and methods for modulating SMN gene family expression (2020-11-17),

12. 10655128 - Compositions and methods for modulating MECP2 expression (2020-05-19),

13. 10519444 - Methods of reducing expression of X-inactivation escapee genes and autosomal genes (2019-12-31),

14. 10358644 - Polycomb-associated non-coding RNAs (2019-07-23),

15. 10208305 - RNA-YY1 interactions (2019-02-19),

Title: Innovations by Jeannie T Lee: A Trailblazer in Molecular Biology

Introduction

Jeannie T Lee is a prominent inventor and researcher based in Boston, MA, well-known for her groundbreaking contributions to molecular biology. With an impressive portfolio of 28 patents, she has made significant strides in understanding cellular mechanisms and therapeutic interventions.

Latest Patents

Among her latest innovations, Lee has developed methods that modulate the cellular stress response. This invention focuses on using B2 or Alu nucleic acids, or antisense oligonucleotides, that can modulate the EZH2/B2 or EZH2/Alu interaction, thereby influencing the cleavage of B2 and Alu RNA to enhance or reduce cell and organismal viability. Another significant patent entails reactivating genes on the inactive X chromosome through the administration of DNA methyltransferase (DNMT) inhibitors and topoisomerase inhibitors, such as etoposide and 5′-azacytidine, possibly in combination with XIST RNA inhibitors or chromatin-modifying proteins.

Career Highlights

Jeannie T Lee has held notable positions at distinguished institutions, including The General Hospital Corporation and Translate Bio, Inc. Her work has been instrumental in advancing the field of genetics and regenerative medicine, with a focus on innovative strategies that manipulate gene expression.

Collaborations

Throughout her career, Lee has collaborated with talented professionals such as Kavitha Sarma and Jing Zhao. These partnerships highlight her commitment to interdisciplinary research and the pursuit of innovative solutions in molecular biology.

Conclusion

Jeannie T Lee stands out as a visionary inventor whose work is paving the way for new therapies and treatments that address complex biological challenges. Her extensive patent portfolio illustrates her dedication to advancing scientific knowledge and her significant impact on the field.

Profile summary based on public USPTO records.